Almirall S.A. is GW’s partner in Europe and therefore any enquiries relating to Sativex® from medical professionals in Europe should be directed to Almirall using their website.

Sativex® is approved in the following countries in mainland Europe: Switzerland, Norway and Turkey.

In all of these countries other than Switzerland the marketing authorization for Sativex® is held by GW Pharma. The marketing authorization for Sativex® in Switzerland is held by Almirall S.A.’s Swiss affiliate.

If you are a medical professional in Europe and would like further information on Sativex® please contact Almirall using the following link:

www.AlmirallMED.com